COMPASS Psilocybin Depression Data Excite Despite Safety Issues

10 Nov 2021

• By Ayisha Sharma

The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.

Thirty Percent Of Treatment-Resistant Depression Patients Attempt Suicide • Source: Alamy

COMPASS Pathways’ sole asset, COMP360, has met its primary endpoint Phase IIb trial in treatment-resistant depression (TRD), albeit racking up serious adverse events along the way.

Nonetheless, given the lack of alternative treatments, the data indicate a clear role for psilocybin-based candidates in patients who do...